Why India Supplies 50% of Global Medicines and Gets 6% of Revenue

In 1990, India and China shared an identical per capita GDP. Over the next three decades, their paths diverged radically. This economic divergence is deeply intertwined with how each nation approached innovation.

Around the turn of the millennium, both countries stood on similar ground regarding medical breakthroughs. Both had discovered almost no original medicine until 2000.

In the years that followed, China systematically linked its macroeconomic growth with aggressive scientific research, operating on the principle that science produces the technology that ultimately produces prosperity.

By 2005, the two nations were still neck and neck in terms of intellectual property receipts, indicating a similar level of recognized domestic innovation.

Yet, in the subsequent two decades, China accelerated its research infrastructure to generate 13 times as many intellectual property receipts as India.

Today, this intellectual engine has transformed the global medical landscape. China now accounts for a third of all global new molecule licensing. China did not just become a cheap factory. It became an indispensable source of new science.

It is nearly impossible for companies that rely on cutting-edge molecules to move away from China.

The current challenges of the Indian pharma industry offer important lessons.

On one hand, India has built an extraordinary manufacturing machine, producing 50% of the world's medicines by volume. This vast output keeps global healthcare systems functional, supplying affordable treatments across continents.

On the other hand, this massive volume does not translate into profits. India captures only 6% of the world's medicine revenues. This gap between the volume of pills produced and the value extracted highlights the hurdles facing the domestic sector.

The industry has historically captured the low-value segments of the global value chain while leaving the high-value, research-intensive segments to others.

To understand how India arrived at this crossroads, one must look at the evolutionary phases of its pharma journey.

The era of Pharma 1.0 was defined by domestic survival and replication, leveraging the 1970 Patents Act to focus heavily on formulations by recognizing process patents rather than product patents. This allowed domestic players to reverse-engineer medicines and provide affordable healthcare to the local population.

The transition to Pharma 2.0 occurred when the industry harnessed the Hatch-Waxman Act of the United States to take its generic manufacturing capabilities global.

As competition intensified and margins squeezed, Pharma 3.0 saw the industry move into complex generics.

Currently, the industry is navigating Pharma 4.0, a phase characterized by launch of new drugs within India before taking them to the global stage.

Under Pharma 4.0, Indian companies spend an average of 8% of their revenue on R&D. While this figure is significantly lower than the Western pharma R&D average of 15% of revenue, it stands far higher than the broader India Inc average of just 1%.

This investment is insufficient for true global leadership in drug discovery.

The upcoming phase, Pharma 5.0, represents future requiring a fundamental paradigm shift from merely making medicines to actively inventing them.

The shift from manufacturing to invention defines the primary challenge for Indian pharma. The historical reliance on generics has left a gap in original drug discovery.

Out of the 5,000+ drugs launched globally over the last decade, only 10 originated from India. In contrast, China broke far ahead in new drug development by completely re-imagining its regulatory approval pathways.

In India, the regulatory approval pathways for clinical trials and new drug launches frequently drag on, taking almost a year. For an industry where a few months of delay can wipe out millions in market value or cost lives, these bureaucratic timelines act as a severe deterrent to innovation.

A modern, globally competitive innovation ecosystem necessitates clear, legally binding timelines for clinical approvals, data reviews, post-marketing surveillance. Without this institutional velocity, MNCs will continue to rely on Chinese research hubs that can clear regulatory hurdles with far greater predictability and speed.

Beyond regulation, the defining battle for Pharma 5.0 centres on capital, which encompasses both finance and talent.

Drug discovery is fundamentally distinct from generic manufacturing. It resembles portfolio finance where the vast majority of projects will fail, meaning institutions must possess the financial stamina to underwrite deep uncertainty.

For India to transition into a global discovery hub, its pharma firms must deliberately raise their R&D spending from the current 8% to at least 12% of revenue.

Furthermore, corporate leadership faces the difficult task of convincing investors about the upside of heavy, short-term costs that may not yield revenues for a decade.

While global buyers want to diversify their risk, they cannot easily replace a Chinese ecosystem that offers massive scale, deep capital pools, rapid regulatory turnarounds, and a third of the world's new molecule licenses.

If India is to capture a larger share of the global revenue pie, it must evolve beyond the factory floor of the world.

For the 5.0 upside in Indian pharma, government and entities must reform its regulatory framework, aggressively pool financial capital, and create an ecosystem where scientists can create the next generation of global therapeutics.

What do you think about the upside potential of Indian Pharma 5.0?

Share your views here.

Warm regards,


Tanushree Banerjee
Editor, StockSelect
Quantum Information Services Private Limited (Research Analyst)